Get the Stockscreener App
0.6126
3.08%
-0.0195
Xilio Therapeutics Inc stock is traded at $0.6126, with a volume of 71,417.
It is down -3.08% in the last 24 hours and down -7.46% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
See More
Previous Close:
$0.632
Open:
$0.6318
24h Volume:
71,417
Relative Volume:
0.12
Market Cap:
$41.21M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2069
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
-2.15%
1M Performance:
-7.46%
6M Performance:
-12.08%
1Y Performance:
-15.16%
1-Day Range:
$0.6052
$0.6401
1-Week Range:
$0.5734
$0.6489
52-Week Range:
$0.5734
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.6101 | 42.69M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.44 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.51 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.61 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.92 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Highs Report: What is Espey Mfg Electronics Corps market positionJuly 2025 Trends & Technical Pattern Recognition Alerts - baoquankhu1.vn
US Stocks Recap: Whats the fair value of Xilio Therapeutics Inc stockShort Setup & Technical Pattern Alert System - baoquankhu1.vn
Xilio Therapeutics (NASDAQ: XLO) reverse split vote to keep listing - Stock Titan
Performance Recap: Is Xilio Therapeutics Inc in accumulation or distribution phase2025 Biggest Moves & High Win Rate Trade Alerts - baoquankhu1.vn
Update Recap: Can Xilio Therapeutics Inc sustain earnings growthJuly 2025 Final Week & Weekly Hot Stock Watchlists - baoquankhu1.vn
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates - Sahm
What dividend safety score for Xilio Therapeutics Inc. stockPortfolio Update Report & Technical Pattern Based Signals - Улправда
How Xilio Therapeutics Inc. stock reacts to bond yieldsWeekly Investment Summary & Weekly High Return Forecasts - Улправда
Is Xilio Therapeutics Inc. stock a contrarian buyEarnings Summary Report & Weekly Sector Rotation Insights - Улправда
Xilio Therapeutics secures $35.8 million from warrant exercises By Investing.com - Investing.com India
Xilio Therapeutics, Inc. Announces Change of Chair of the Board of Directors - MarketScreener
Why Xilio Therapeutics Inc. stock attracts high net worth investorsWeekly Trend Summary & Breakout Confirmation Alerts - ulpravda.ru
Xilio Therapeutics extends cash runway into 2027 - MSN
Xilio Therapeutics Inc appoints Sara Bonstein as chair of board - MarketScreener
Xilio Therapeutics Announces Leadership Transition and Pipeline Updates - TipRanks
Xilio Therapeutics Announces Board Leadership Change - TradingView — Track All Markets
Is Xilio Therapeutics Inc. stock supported by strong fundamentalsMarket Risk Analysis & Safe Entry Point Alerts - Улправда
Xilio Therapeutics secures $35.8 million from warrant exercises - Investing.com
Xilio Therapeutics (NASDAQ: XLO) updates cash and appoints new board chair - Stock Titan
Xilio Therapeutics Extends Cash Runway Into 2027 - The Globe and Mail
Xilio shares soar on AbbVie collaboration deal - MSN
Xilio Therapeutics reports $35.8 million in proceeds from Series B warrant exercises By Investing.com - Investing.com South Africa
Xilio Therapeutics reports $35.8 million in proceeds from Series B warrant exercises - Investing.com Nigeria
Xilio Therapeutics Series B and C Warrants Update - TradingView — Track All Markets
Head to Head Review: Xilio Therapeutics (NASDAQ:XLO) and Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Decrease in Short Interest - Defense World
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 0.5% – What’s Next? - Defense World
Xilio Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Will Xilio Therapeutics Inc. stock reach all time highs in 20252025 Market Overview & High Accuracy Swing Trade Signals - bolumsonucanavari.com
Can Xilio Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 PreEarnings & Risk Managed Investment Strategies - Улправда
Is Xilio Therapeutics Inc. stock dividend yield sustainableWeekly Market Report & High Conviction Investment Ideas - Улправда
Is Xilio Therapeutics Inc. stock a defensive play in 2025July 2025 Sector Moves & Free Fast Gain Swing Trade Alerts - Улправда
Loss Report: Can Xilio Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 EndofMonth & High Win Rate Trade Alerts - Улправда
Why Xilio Therapeutics Inc. stock remains undervaluedJuly 2025 Reactions & High Win Rate Trade Tips - bolumsonucanavari.com
Xilio Therapeutics Inc (XLO) looking to reclaim success with recent performance - setenews.com
Xilio Therapeutics Inc (XLO) can make a big difference with a little luck - setenews.com
Xilio Therapeutics, Inc. (XLO) -5.65% in After-hours: Slide Amid Routine Trading Conditions - Stocks Telegraph
Is Xilio Therapeutics Inc. stock trading at a premium valuationJuly 2025 Sentiment & Fast Gain Swing Alerts - Newser
Why Xilio Therapeutics Inc. stock is trending among retail traders2025 Price Action Summary & Expert Curated Trade Ideas - Newser
Can Xilio Therapeutics Stock Recover If Markets Fall? - Trefis
Recap Report: Why Xilio Therapeutics Inc. stock attracts high net worth investorsProduct Launch & High Accuracy Investment Signals - moha.gov.vn
Xilio Therapeutics announces pricing of $50 million public offering - MSN
Xilio Therapeutics Approves 2025 Stock Incentive Plan - MSN
[S-8] Xilio Therapeutics, Inc. Employee Benefit Plan Registration | XLO SEC FilingForm S-8 - Stock Titan
[Form 4] Xilio Therapeutics, Inc. Insider Trading Activity - Stock Titan
[8-K] Xilio Therapeutics, Inc. Reports Material Event | XLO SEC FilingForm 8-K - Stock Titan
AbbVie and Xilio partner for tumor-activated therapies - MSN
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):